Abemaciclib APIs provided by Loncom Pharma are crucial in the development of CDK4 & 6 inhibitors for the treatment of HR-positive, HER2-negative breast cancer, offering a strategic approach to halt the progression of cancer cells.
Shandong Loncom Pharmaceutical Co., Ltd is founded in 2012, located in Qihe Economic Development Zone, Shandong Province, with a registered capital of 60 million yuan.
